# Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

> **NCT01714817** · PHASE3 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 695 (actual)

## Conditions studied

- Lupus Nephritis

## Interventions

- **BIOLOGICAL:** BMS-188667
- **DRUG:** Mycophenolate mofetil
- **DRUG:** Prednisone
- **BIOLOGICAL:** Placebo matching with BMS-188667

## Key facts

- **NCT ID:** NCT01714817
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01-22
- **Primary completion:** 2016-11-21
- **Final completion:** 2018-05-30
- **Target enrollment:** 695 (ACTUAL)
- **Why stopped:** Inability to meet protocol objectives.
- **Last updated:** 2021-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01714817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01714817, "Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01714817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*